Mahmarian et al. (1) recently published the INSPIRE (AdenosINe Sestamibi SPECT Post-InfaRction Evaluation) trial, a prospective study comparing intensive medical therapy to revascularization in stable patients following ST-segment elevation myocardial infarction (STEMI) or non-STEMI with demonstrable ischemic burden on myocardial perfusion imaging (MPI). Medical therapy was shown to be equivalent to revascularization, decreasing the ischemic burden at 2 months assessed by repeat MPI. The 1-year clinical outcomes were also assessed, but the study was not powered to detect any differences, and, predictably, did not.
